Viemed Healthcare, Inc.

What they do

Viemed provides home medical equipment, primarily through monthly rental arrangements, including home ventilation (invasive and non-invasive), BiPAP and CPAP devices, percussion vests, and oxygen concentrators. Its service programs include respiratory disease management for conditions such as COPD, neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, associated supplies, women's health products and services, and healthcare staffing. The company serves patients in all 50 states and employed 401 licensed respiratory therapists as of December 31, 2025, about 29% of its employee count.

Revenue drivers

• Home medical equipment rentals — Primarily monthly rental arrangements for ventilators, BiPAP and CPAP devices, percussion vests, and oxygen concentrators; the company ended Q2 2026 with a record 12,635 ventilator patients.
• PAP therapy and sleep resupply — CPAP/BiPAP therapy and related resupply; PAP therapy patient count reached 37,825 as of June 30, 2026, up 44.0% year over year, and sleep resupply patient count was 37,035, up 46.7% year over year.
• Respiratory disease management and neuromuscular care — High-touch clinical programs for COPD and neuromuscular patients using non-invasive ventilation, percussion vests, and other therapies, aimed at reducing hospital readmissions.
• Women's health and healthcare staffing — Women's health products and services and external healthcare staffing and recruitment solutions; the company cited continued expansion in maternal health and staffing services among its growth engines.

Recent performance

For the quarter ended June 30, 2026, net revenues were a record $78.1 million, up $15.0 million or 23.9% from the prior-year quarter and up about 3.6% sequentially. Net income attributable to Viemed was $2.8 million, or $0.07 per diluted share, while Adjusted EBITDA was $13.7 million, down 4.0% year over year against a prior-year period that included a $1.0 million non-recurring gain on equipment disposal. Operating cash flow was $15.9 million for the quarter and $60.8 million for the trailing twelve months, with free cash flow of $8.6 million and $34.4 million, respectively. The company repurchased 530,802 shares for $5.1 million at an average price of $9.65 during the quarter, and ended with $10.7 million in cash, $6.4 million of long-term debt, and $46 million available under credit facilities.

Strategy

Viemed seeks to grow by increasing patients served and expanding existing service areas as well as launching in new territories through a cost-efficient model that reduces location expenses. It focuses overhead on patient-facing personnel such as respiratory therapists rather than physical locations to scale efficiently in underserved territories. The company continues investing in people, technology, and patient care capabilities to support patient growth entering the platform. It is expanding its licensed clinical practitioner workforce, including respiratory therapists, while providing external healthcare staffing services. Management also repurchases shares under its repurchase program and reduced capital intensity by growing less capital-intensive product and service revenue.

Risks

• Reimbursement rate pressure — Reimbursement primarily comes from Medicare, Medicaid, and private insurers, and rates are outside the company's control and subject to reductions that could materially harm profitability.
• Payor concentration — The business depends on a limited number of payors, and reductions in reimbursement rates or audits of claims by governmental and private payors are cited as risks.
• Competition from larger rivals — The respiratory care industry is highly competitive, and some competitors are subsidiaries or divisions of larger, better-capitalized companies with vertically integrated manufacturing and services.
• Regulatory and licensing exposure — The company operates in a highly regulated business requiring permits and licenses, and changes in or application of laws and regulations could affect operations.

Outlook

Management raised the low end of and narrowed full-year 2026 net revenue guidance to $314 million to $320 million, from a previous range of $312 million to $320 million. Adjusted EBITDA guidance was revised to $64 million to $68 million from $65 million to $69 million, and net capital expenditures are now expected at 8.5% to 10.0% of net revenue, down from 9.0% to 10.5%. The company said the revisions reflect growing contribution from less capital-intensive product and service revenue and that it enters the second half of 2026 confident in delivering consistent, increasingly predictable growth.